Morgan Stanley On Johnson & Johnson: Believes 'the stock reaction is not supported by science and may inflate potential legal exposure'; Sees Comparisons To Recent Legal Issues At Bayer (BAYRY) As Flawed; Maintains Overweight, $153 Target